Collegium Pharmaceutical, Inc.
COLL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $925 | $1,039 | $785 | $653 |
| - Cash | $71 | $239 | $174 | $186 |
| + Debt | $980 | $674 | $873 | $259 |
| Enterprise Value | $1,834 | $1,474 | $1,484 | $725 |
| Revenue | $631 | $567 | $464 | $277 |
| % Growth | 11.4% | 22.2% | 67.6% | – |
| Gross Profit | $377 | $326 | $209 | $151 |
| % Margin | 59.8% | 57.5% | 45.2% | 54.4% |
| EBITDA | $342 | $308 | $173 | $87 |
| % Margin | 54.1% | 54.4% | 37.4% | 31.3% |
| Net Income | $69 | $48 | -$25 | $72 |
| % Margin | 11% | 8.5% | -5.4% | 25.8% |
| EPS Diluted | 1.86 | 1.29 | -0.74 | 1.86 |
| % Growth | 44.2% | 274.3% | -139.8% | – |
| Operating Cash Flow | $205 | $275 | $124 | $104 |
| Capital Expenditures | -$2 | -$0 | -$2 | -$2 |
| Free Cash Flow | $203 | $274 | $123 | $102 |